Previous 10 | Next 10 |
2023-05-08 16:25:56 ET Theravance Biopharma press release ( NASDAQ: TBPH ): Q1 GAAP EPS of -$0.35 misses by $0.10 . Revenue of $10.4M (-21.2% Y/Y) misses by $3.3M . On track to complete $325 million capital return program by year-end. TBPH reaffirms its exp...
Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update PR Newswire Q1 2023 YUPELRI ® (revefenacin) net sales of $47.0 million , recognized by Viatris, up 8% from Q1 2022 1 Q1 2023 YUPELRI retail new p...
2023-05-03 04:45:48 ET Summary Theravance Biopharma has recently come under pressure from a reputable activist investor, Irenic Capital. The activist is pushing the company to initiate a large capital return and launch a strategic review. Shortly after the pushback from Irenic...
Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023 PR Newswire DUBLIN , April 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2023 financial results and provide a business update aft...
2023-04-12 13:19:01 ET Theravance Biopharma ( NASDAQ: TBPH ) rose 0.4% as the company announced it appointed a new director to the board. Theravance ( TBPH ) added Jim Kelly, Managing Director at Weiss Asset Management, the company's second largest shareholder, to its bo...
Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors PR Newswire DUBLIN , April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBP...
2023-04-10 10:48:10 ET A group of senior pharma executives, including Pfizer ( NYSE: PFE ) chief executive Albert Bourla, has come forward in support of the FDA after a Texas-based judge suspended the approval of abortion treatment mifepristone on Friday. Mifepristone, appro...
2023-03-08 14:09:19 ET The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Theravance Biopharma, Inc. 2022 Q4 - Results - Earnings Call Presentation
Theravance Biopharma Inc. (TBPH) Q4 2022 Results Conference Call February 27, 2023 05:00 PM EST Company Participants Rick Winningham - Chairman and Chief Executive Officer Rhonda Farnum - Senior Vice President, Chief Business Officer Rick Graham - Senior Vice President...
Theravance Biopharma press release ( NASDAQ: TBPH ): Q4 GAAP EPS of -$0.15 beats by $0.02 . Revenue of $14.6M (-2.3% Y/Y) misses by $1.13M . Discontinuing investments in research, reducing headcount by approximately 17%. Increases capital return program to $325 mil...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 PR Newswire DUBLIN , July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2024 financial results and provide a business update...
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...